Beyond Traditional Lipid Lowering: Obicetrapib and the Renaissance of Cholesteryl Ester Transfer Protein Inhibition

Abstract

Obicetrapib, a next-generation cholesteryl ester transfer protein (CETP) inhibitor, is emerging as a potent therapeutic option to address residual cardiovascular risk in patients not achieving optimal outcomes with existing lipid-lowering therapies, such as statins, ezetimibe and proprotein convertase subtilisin/kexin type 9 inhibitors. Many high-risk individuals fail to meet recommended LDL cholesterol targets, and up to 40% experience recurrent cardiovascular events, highlighting the need for novel interventions. This review consolidates the evidence from Phase I–III trials (including TULIP, ROSE, BROADWAY, BROOKLYN and TANDEM) and meta-analyses. Take together, the results demonstrate that obicetrapib significantly reduces LDL cholesterol by 30–50%, apolipoprotein B by 20–30% and lipoprotein(a) by as much as 40-50%, while elevating HDL cholesterol levels by more than 100%. The average LDL cholesterol reduction was 0.92 mmol/l (35.4 mg/dl), with amplified effects when combined with ezetimibe. Obicetrapib achieves up to 97% inhibition of CETP activity and maintains a favourable safety profile. Additional metabolic benefits include decreased HbA_1c and a lower incidence of new-onset diabetes. These results highlight obicetrapib’s robust efficacy across multiple lipid parameters and its contribution to atherogenic lipoprotein reduction, particularly lipoprotein(a), a marker of high residual risk. Overall, obicetrapib represents a meaningful advancement in cardiovascular risk management and is positioned as an important new agent for high-risk patients with persistent residual risk despite current standard-of-care therapies.

Atherosclerotic cardiovascular disease (ASCVD) continues to be a predominant cause of morbidity and mortality globally, despite substantial progress in lipid-lowering therapeutic interventions. Over the past decades, LDL cholesterol (LDL-C) and apolipoprotein B (ApoB)-containing lipoproteins have been firmly established as the primary causal agents in the development of atherosclerosis.1 Extensive research has shown that reducing LDL-C levels translates into a substantial decrease in cardiovascular events, with statins forming the cornerstone of this therapeutic strategy. Landmark clinical trials confirm a consistent relationship: approximately every 1 mmol/l reduction in LDL-C corresponds to a 22% reduction in major atherosclerotic cardiovascular events.2 This principle has reshaped cardiovascular medicine, saving millions of lives globally. Nonetheless, a significant portion of patients continue to face residual cardiovascular risk even after achieving guideline-recommended LDL-C targets with statin therapy.

The Apolipoprotein B Awakening: Moving Beyond LDL Cholesterol Tunnel Vision

Up to 40% of individuals on optimised statin regimens still experience recurrent cardiovascular events, highlighting the limitation of an LDL-C centric approach.3 This observation has shifted focus toward a broader assessment of atherogenic lipoprotein particles, particularly the measurement of ApoB, which reflects the total number of these atherogenic particles. Unlike LDL-C, which solely measures cholesterol concentration within LDL particles, ApoB quantifies all circulating atherogenic particles, including LDL-C, very low density lipoprotein cholesterol (VLDL-C), intermediate-density lipoproteins and lipoprotein(a) [Lp(a)]. Evidence indicates that ApoB is a superior marker of cardiovascular risk.4

Lipoprotein(a): The Silent Cardiovascular Assassin We Cannot Ignore

Lp(a) is a critical, genetically determined lipoprotein contributing to residual cardiovascular risk. Elevated Lp(a) levels, present in approximately 20% of the population, are linked to a higher risk of ASCVD and are largely unaffected by traditional lipid-lowering agents, such as statins and ezetimibe.5 This persistent risk factor further emphasises the need for novel, complementary therapies that target the total atherogenic particle burden beyond LDL-C.

There is a pressing demand for effective and well-tolerated lipid-lowering therapies that address these unmet needs. Obicetrapib, a novel cholesteryl ester transfer protein (CETP) inhibitor, has emerged as a promising candidate, potentially filling the therapeutic gap by significantly lowering LDL-C and impacting other lipoprotein fractions with greater efficacy and safety.

This review explores the evolving landscape of lipid management and emphasises the potential role of obicetrapib in redefining cardiovascular risk reduction.

The Cholesteryl Ester Transfer Protein Inhibition Hypothesis

Epidemiological studies have shown that higher levels of HDL cholesterol (HDL-C) are generally associated with a lower risk of ASCVD.6 Additionally, genetic mutations in the CETP gene that lead to increased HDL-C and decreased LDL-C levels have sparked interest in developing CETP inhibitors as a therapeutic strategy.7

CETP inhibitors were initially designed to raise HDL-C levels to help prevent cardiovascular events. Their primary mechanism is to block the transfer of cholesteryl esters (CE) from HDL particles to triglyceride-rich lipoproteins (TRLs), which include VLDL, chylomicrons and their remnants. By inhibiting this transfer, the CE content in HDL increases, producing larger HDL particles that persist longer in the circulation. At the same time, there is a decrease in CE content in TRLs and LDL. This reduction is likely due to decreased CE transfer from HDL to TRLs, lowered CE content in VLDL (which converts into LDL) and increased breakdown (catabolism) of LDL-C particles (Figure 1A and 1B).

Figure 1: Mechanism of Action of the Potent Cholesteryl Ester Transfer Protein Inhibitor Obicetrapib.

A: CETP inhibition diminishes LDL-C levels through three mechanisms: (1) reduced transfer of HDL CE into TRL, which are subsequently converted into LDL; (2) decreased transfer of HDL CE into LDL; and (3) increased hepatic uptake of LDL particles via the LDL-R. B: Given that LDL-C catabolism is predominantly facilitated by LDL-R-mediated clearance within the liver, the observed increase in LDL catabolism among subjects treated with a CETP inhibitor likely indicates an enhancement in the clearance of LDL-C particles via the LDL-R pathway. This phenomenon may be attributable to a relative depletion of the regulatory cholesterol pool in the liver, consequent to CETP inhibition, which consequently results in an upregulation of LDL-R mRNA. CE = cholesteryl ester; CETP = cholesteryl ester transfer protein; LDL-C = LDL cholesterol; LDL-R = LDL receptor; mRNA = messenger RNA; TG = triglyceride; TRL = triglyceride-rich lipoproteins. A: Created in BioRender. Pradhan A. (2026) https://BioRender.com/l4cde46. B: Created in BioRender. Pradhan A. (2026) https://BioRender.com/b30lwox

As a result, CETP inhibition simultaneously raises HDL-C levels while lowering non-HDL-C, which includes cholesterol from TRLs and LDL. Moreover, the reduction in CE transfer contributes to a decrease in ApoB levels in VLDL and LDL particles (Table 1).

Table 1: Mechanistic Effects of Cholesteryl Ester Transfer Protein Inhibition.

Pathway	Effect of CETP Inhibition
HDL metabolism	↓ CE transfer from HDL leads to ↑ HDL (larger particles, slower clearance)
LDL metabolism	↓ CE transfer to VLDL leads to ↓ LDL and VLDL
ApoB	↓ ApoB synthesis (fewer VLDL leads to LDL particles)
Lp(a)	↓ ApoA synthesis, reduced CE transfer

ApoA = apolipoprotein A; ApoB = apolipoprotein B; CE = cholesteryl ester; CETP = cholesteryl ester transfer protein; Lp(a) = lipoprotein(a); VLDL = very LDL; ↓ = decrease; ↑ = increase.

Metabolic studies on individuals with mild hypercholesterolaemia treated with anacetrapib – a CETP inhibitor – have shown that the decreases in VLDL-C and LDL-C levels resemble those seen in people with genetic CETP deficiency. These effects are mainly due to increased catabolism of these particles. Additionally, anacetrapib lowers Lp(a) levels by reducing the synthesis of apolipoprotein A (ApoA). When used alongside statins, anacetrapib also modestly lowers plasma triglyceride levels, suggesting enhanced breakdown of VLDL triglycerides.

Evidence supporting CETP inhibition as a therapeutic strategy have emerged from human genetics and preclinical models:

• Genetic insights: Individuals with CETP deficiency due to loss-of-function mutations exhibit markedly elevated HDL-C and reduced ASCVD incidence.8 The Copenhagen City Heart Study and others have linked CETP polymorphisms with lower rates of myocardial infarction and cardiovascular mortality.9

• Animal models: CETP knockout models developed atherosclerosis at a significantly slower pace, while animals transgenically expressing CETP developed accelerated disease.10

Together, these findings established biological plausibility for CETP inhibition as a conceptually attractive mechanism to attenuate ASCVD risk by simultaneously lowering ApoB-containing particles and boosting HDL-C – the so-called ‘reverse cholesterol transport’ pathway.

Research indicates that an increase in HDL-C does not invariably correlate with a reduction in cardiovascular events or mortality. A review by Mamede et al. revealed no significant change in all-cause or cardiovascular mortality associated with elevated HDL-C levels. Notably, very high HDL-C levels (>116 mg/dl in women and >94 mg/dl in men) have been associated with an increased risk of cardiovascular mortality.11

Additionally, a Chinese study has demonstrated that both low and high HDL-C concentrations are associated with an increased mortality risk.12 The AEGIS-II and HPS2-THRIVE trials, both of which examined therapies aimed at elevating HDL-C levels to enhance cardiovascular outcomes, failed to demonstrate significant clinical benefits.13,14

Lessons From Early Cholesteryl Ester Transfer Protein Inhibitor Studies

Initial promise, subsequent failures and eventual redemption have marked the CETP field (Table 2).

Table 2: Major Cholesteryl Ester Transfer Protein Inhibitors and Clinical Trial Outcomes.

CETP Inhibitor	Trial	Dose	n	Change in LDL-C	Change in HDL-C	Change in Lp(a)	Change in ApoB	Outcome
Torcetrapib	ILLUMINATE15	60 mg	15,067	-25%	+72%	NR	-15%	↑ Mortality (off-target toxicity)
Dalcetrapib	Dal-OUTCOMES16	600 mg	15,871	-5%	+31–40%	No change	No change	Neutral
Anacetrapib	REVEAL18	100 mg	30,449	-17%*	+104%	-25%	-18%	↓9% MACE after 4 years; Extended follow-up further 20% reduction in coronary events
Evacetrapib	ACCELERATE17	130 mg	12,092	-31%	+133%	-22.3%	-15.5%	Neutral

*LDL-C estimation with the beta quantification method in a randomly selected trial subpopulation of 2000. ApoB = apolipoprotein B; CETP = cholesteryl ester transfer protein; Lp(a) = lipoprotein a; MACE = major adverse cardiovascular events; NR = not reported.

Torcetrapib was evaluated in the ILLUMINATE trial. Although torcetrapib raised HDL-C by 72% and lowered LDL-C by ~25%, it was associated with increased mortality due to off-target adverse effects (elevated aldosterone, potassium, blood pressure, vascular toxicity). The programme was terminated in 2006.15

Dalcetrapib was evaluated in the dal-OUTCOMES trial, which showed that dalcetrapib raised HDL-C by 31–40% but produced a non-significant LDL-C reduction.16 Cardiovascular outcomes showed no benefit, leading to early discontinuation.

In the ACCELERATE trial, the potent CETP inhibitor evacetrapib yielded ~131% increases in HDL-C and ~37% reductions in LDL-C. However, after 2.2 years of follow-up in over 12,000 patients, no cardiovascular benefit was demonstrated.17

Finally, the REVEAL trial of anacetrapib marked the turning point. Over 30,000 high-risk patients followed for 4.1 years experienced a 9% proportional reduction in major adverse cardiovascular events (MACE). Unlike its predecessors, anacetrapib combined potency, safety and adequate duration of exposure.18

Limitations of Current Therapies

ASCVD remains a significant global health burden with increasing significance. According to the WHO Global Health Estimates, coronary artery disease and stroke are the primary causes of mortality globally.19 In 2019, nearly 15.1 million deaths were attributed to these conditions, a 24% increase since 2000, and the numbers are expected to rise further due to the growing prevalence of obesity, diabetes and metabolic syndrome.19 Socioeconomic changes have further accelerated the rise of ASCVD incidence globally.20

Prevention of ASCVD focuses on promoting healthy lifestyles and addressing key risk factors, such as ApoB, LDL-C, hypertension and diabetes. Statin therapy and ezetimibe remain the primary treatments for lowering LDL-C across all risk categories. For patients at higher risk, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors may be added to optimise LDL-C reduction. However, widespread use of statins is often limited by intolerance, and PCSK9 inhibitors are less frequently used due to high costs and limited accessibility.

Recent European cross-sectional data highlight substantial gaps in achieving LDL-C target levels: only 18% of individuals at very high risk achieved the recommended LDL-C goal (1.4 mmol/l). Success rates for LDL-C target attainment varied across risk groups – 60% for high risk, 25% for moderate risk and 63% for low risk. Among those at very high risk treated with statin monotherapy, success rates were 22%, 16% and 14% for high-, moderate- and low-intensity statins, respectively.21

This persistent discrepancy between guideline-recommended LDL-C goals and real-world target achievement underscores the urgent need for adjunctive non-statin LDL-C-lowering therapies, particularly for those at the highest risk. Evidence from clinical trials involving statins, ezetimibe and PCSK9 inhibitors and the REVEAL trial with CETP inhibition consistently shows that cardiovascular benefits correlate closely with the magnitude of LDL-C and ApoB reductions, as well as treatment duration. Importantly, these benefits appear independent of the therapeutic modality used to lower LDL-C.

CETP inhibitors represent a promising addition to existing therapies, especially for patients intolerant to statins. Novel CETP inhibitors have demonstrated favourable safety profiles. While anacetrapib showed efficacy in reducing ASCVD events in the REVEAL trial, obicetrapib has been proven to lower LDL-C and ApoB levels by approximately twice as much, potentially translating into greater reductions in cardiovascular risk.

Obicetrapib: The Next-generation Solution to an Old Problem

Obicetrapib is recognised as the most polar CETP inhibitor, with a chemical structure that probably enhances its binding affinity and specificity. It can reduce CETP activity by up to 97%. Following daily doses of 5 mg and 10 mg, it has a mean half-life of approximately 130–150 hours.22

Obicetrapib Clinical Trials and Meta-analyses

Phase I Trials

The CHINESE trial was a randomised, open-label study that evaluated the pharmacokinetic, pharmacodynamic and safety profiles of single and multiple oral doses of obicetrapib in healthy Chinese adults.23 Single doses of 5 mg, 10 mg and 25 mg demonstrated dose-dependent increases in plasma concentration and exposure, with a peak around 4 hours and a long half-life. Multiple dosing of 10 mg daily for 14 days reached steady state with significant CETP inhibition, LDL-C reduction by 42% and HDL-C increase by 108%. The safety profile was favourable, with only one mild treatment-related adverse event reported.23

Phase II Trials

The TULIP double-blind randomised study was conducted in Denmark and the Netherlands.24 Eligible individuals had LDL-C of 2.5–4.5 mmol/l, triglyceride levels <4.5 mmol/l and HDL-C levels 0.8–1.8 mmol/l after a washout period from prior lipid-lowering therapies. Individuals were randomised 1:1 to receive one of nine treatments: a once-daily dosage of obicetrapib (TA-8995; 1 mg, 2.5 mg, 5 mg or 10 mg), a matching placebo, 10 mg obicetrapib and 20 mg atorvastatin or 10 mg obicetrapib and 10 mg rosuvastatin. The primary endpoint was the alteration in HDL-C and LDL-C levels at week 12 from baseline, assessed based on intention-to-treat principles. A total of 364 individuals were included in the study. By week 12, LDL-C levels decreased by 27% with 1 mg, 32% with 2.5 mg and 45% with both 5 mg and 10 mg doses (p<0.0001). Individuals who received a combination of obicetrapib plus atorvastatin experienced a 68% reduction in LDL-C, while those receiving obicetrapib with rosuvastatin had a 63% reduction (p<0.0001). Regarding HDL-C, the increases observed were 75% for the 1 mg dosage, 124% for the 2.5 mg dosage, 157% for the 5 mg dosage and 179% for the 10 mg dosage (p<0.0001). Patients receiving a combination of obicetrapib with atorvastatin experienced a 152% increase in HDL-C, and those taking a combination of obicetrapib and rosuvastatin showed a 157% increase. During the trial, no significant adverse events or indications of musculoskeletal or hepatic toxicity were observed.24

ROSE was a double-blind, randomised trial that evaluated the effects of obicetrapib on lipid profile in 120 individuals with dyslipidaemia, with a median LDL-C level of 2.2 mmol/l (88 mg/dl) while receiving background high-dose statin treatment.25 Over 8 weeks, administering obicetrapib at doses of 5 and 10 mg led to a substantial decrease in LDL-C levels, with reductions of up to 51% in comparison to the placebo group (p<0.0001). Additionally, the treatment demonstrated a noteworthy decrease in ApoB levels, with reductions of up to 30%. Moreover, non-HDL-C levels decreased significantly by up to 44%. Conversely, HDL-C levels rose significantly, with improvements of up to 165%. The trial also indicated that obicetrapib exhibited an acceptable safety profile, suggesting its potential to address the needs of patients at high cardiovascular risk. This study provides valuable insights into lipid management strategies and highlights the potential of obicetrapib in improving patient outcomes.25

ROSE2 assessed the efficacy and safety of ezetimibe and obicetrapib, combined with a high-intensity statin.26 This randomised double-blind trial administered obicetrapib and 10 mg ezetimibe (n=40), obicetrapib alone (n=39) or placebo (n=40) to individuals with LDL-C levels >1.8 mmol/(>70 mg/dl) for 12 weeks and triglycerides <400 mg/dl, with all participants on statin therapy. Ninety-seven individuals (mean age 62.6 years; 84.5% white; 63.9% men; mean BMI 30.9 kg/m²) were included in the analysis.

LDL-C levels decreased by 6.35% in the placebo arm, 43.5% in the obicetrapib arm and 63.4% in the combined therapy arm (p<0.0001). Patients undergoing combination therapy attained LDL-C target levels of less than 2.6 mmol/l (100 mg/dl), 1.8 mmol/l (70 mg/dl) and 1.4 mmol/l (55 mg/dl) at rates of 100%, 93.5% and 87.1%, respectively. Both treatments significantly decreased ApoB, non-HDL-C, total and small-dense LDL-C particles. Obicetrapib had good tolerability with no safety concerns observed. The obicetrapib and ezetimibe combination significantly lowered lipid levels and demonstrated no drug-related serious adverse events during treatment in conjunction with high-intensity statins in patients with elevated LDL-C (Table 3).26

Table 3: Change in Lipid Parameters with Obicetrapib Therapy.

	Monotherapy (BROOKLYN trial29)	Combination Therapy with Ezetimbibe (TANDEM trial27)
LDL-C ↓	36.3%	48.6%
Non-HDL-C ↓	34.5%	45.1%
Sd LDL-C ↓	102.4%	87.1%*
ApoB ↓	24.4%	29.2%
Lp(a) ↓	45.9%	62.9%
HDL-C ↑	138.7%	128.5%

*Data from the ROSE2 study.26 ApoB = apolipoprotein B; Lp(a) = lipoprotein (a); HDL-C = HDL cholesterol; LDL-C = LDL cholesterol; non-HDL-C = non-HDL cholesterol; Sd LDL-C = small dense LDL cholesterol.

Methodologically, the Phase II trials were well designed as they were randomised, double-blind, placebo-controlled and conducted on a background of high-intensity statin therapy. These trials used contemporary LDL-C targets and additionally measured relevant secondary markers such as Lp(a) and ApoB. However, they were modest in size, featuring hundreds rather than thousands of participants, with a short duration of 8–12 weeks. They primarily involved European populations and heterozygous familial hypercholesterolaemia (HeFH)/ASCVD patients, and were not powered to detect clinical events. Therefore, they primarily validate the pharmacological effects, rather than clinical outcomes or rare toxicities.

Phase III Trials

The TANDEM double-blind, randomised trial was conducted at 48 sites in the US. Participants aged ≥18 years had either a pre-existing ASCVD condition or were at high ASCVD risk or HeFH, with LDL-C of ≥ 1.4 mmol/l (>70 mg/dl) despite maximally tolerated lipid-lowering therapy.

Participants were randomly allocated to one of four groups: obicetrapib combined with ezetimibe fixed-dose combination (FDC), ezetimibe alone, obicetrapib alone or placebo, all administered for 12 weeks. Co-primary endpoints included percentage changes in LDL-C levels comparing the FDC to placebo, ezetimibe and obicetrapib. Overall 407 participants were enrolled, with a median age of 68 years (43% women). Mean baseline LDL-C levels were 2.4 mmol/l for placebo (n=102), 2.5 mmol/l for ezetimibe (n=101), 2.6 mmol/l for obicetrapib (n=102) and 2.5 mmol/l for FDC (n=102).

At 12 weeks, the FDC arm showed a reduction in LDL-C of 48.6% compared to the placebo, 27.9% compared to ezetimibe and 16.8% compared to obicetrapib. Obicetrapib reduced LDL-C by 32% to placebo while ezetimibe reduced LDL-C by 21% only. Adverse events were comparable among the treatment groups, with the lowest incidence observed in the placebo arm. Serious adverse events were similarly distributed across the groups. Deaths were documented in one participant within each of the treatment arms, with no fatalities reported in the placebo group.

The results demonstrated that obicetrapib plus ezetimibe FDC significantly and safely reduces LDL-C in high-risk patients, offering a convenient oral single-pill option to improve LDL-C management beyond conventional therapies.27

From a clinical perspective, TANDEM offers a convenient high-potency oral combination that may rival PCSK9 pathway inhibitors in patients requiring an additional LDL-C reduction of ≥50% while preferring an oral agent. Nevertheless, similar to the monotherapy Phase II trials mentioned above, the follow-up period was brief (approximately 3–12 months), and there were no prespecified primary endpoints for MACE. Additionally, the available data are predominantly summarised through topline communications, which constrains detailed evaluation of subgroups, adherence and off-target effects.

The BROADWAY trial was a multinational, randomised, placebo-controlled trial that involved individuals with a history of ASCVD or HeFH who had already received maximum tolerable doses of lipid therapy. Eligible participants had LDL-C >2.6 mmol/l (100 mg/dl) and a non-HDL-C >3.4 mmol/l (130 mg/dl). Participants were randomly assigned in a 2:1 ratio to receive 10 mg obicetrapib or a matching placebo for 365 days. The primary objective was the percentage change in LDL-C at day 84. A total of 2,530 individuals were randomised, with 1,686 receiving obicetrapib and 844 receiving a placebo. The average age was 65 years, 34% of participants were women and the average baseline LDL-C was 98 mg/dl. At day 84, the average percentage reduction in LDL-C was -29.9% for obicetrapib versus 2.7% for placebo, resulting in a significant difference of -32.6 percentage points (p<0.001). Adverse events were similar in both groups. LDL-C reduction was 29.9% in high-risk patients already on optimum lipid-lowering therapy with obicetrapib. In this trial, obicetrapib added to maximal lipid-lowering therapy significantly lowered LDL-C and was well tolerated in high-risk patients.28

The BROOKLYN trial assessed the safety, effectiveness and tolerability of obicetrapib as an add-on therapy for individuals with HeFH who were unable to achieve adequate LDL-C control despite maximum tolerated therapy. This randomised, double-blind trial encompassed a 1-year follow-up, involving 354 individuals across 70 centres. Eligible participants (n=354) had HeFH alongside LDL-C levels of > 1.8 mmol/l (>70 mg/dl) while on lipid-modifying therapies that were maximally tolerated. They had been randomised to obtain 10 mg obicetrapib or a matching placebo every day in a 2:1 ratio for 52 weeks. The least squares analysis assessed the mean percentage change in LDL-C at week 12. Secondary endpoints comprised alterations in non-HDL-C, ApoB, HDL-C, total cholesterol, Lp(a) and triglycerides, along with safety protocols. ApoA1 was an exploratory endpoint. Obicetrapib significantly reduced average LDL-C at 12 weeks by 36.3% and at 1 year by 41.5% compared to placebo. There were reductions in mean ApoB (-24.4% and -25.8%), non-HDL-C (-34.5% and -37.5%) and Lp(a) (-45.9% and -54.3%), and increases in HDL-C (138.7% and 121.4%). Obicetrapib was well tolerated, without any severe adverse effects or alterations in ECGs or laboratory results. These results indicate that obicetrapib combined with lipid-modifying therapies that are maximally tolerated may significantly decrease LDL-C levels in individuals with HeFH, providing a promising therapeutic option for those unable to meet their treatment goals (Table 3).29,30

BROOKLYN (HeFH) and BROADWAY (ASCVD/HeFH with uncontrolled LDL-C or non-HDL-C despite maximally tolerated therapy) are critical for regulatory approval, and both achieved primary endpoints with statistically significant LDL-C reductions compared with placebo.28,29 The safety profile observed in these clinical trials appears to be reassuring. Overall, adverse events, elevations in liver enzymes, increases in creatine kinase, glycaemic parameters and renal function metrics were comparable to or better than those observed with placebo. There were no apparent signals of off-target effects, such as elevated blood pressure, increased aldosterone levels or infections, which have previously been associated with CETP inhibitors. Notably, both trials incorporated MACE as secondary or adjudicated endpoints. The data indicate a numerical reduction in cardiovascular events with obicetrapib (for example, a BROADWAY HR of approximately 0.79). However, these studies are underpowered for a definitive assessment of outcomes and display wide confidence intervals that cross unity.

Critical gaps do persist. First, as yet, there is no completed dedicated outcomes trial, so benefits on MACE are inferred from surrogates, prior anacetrapib experience and short, underpowered event data. Second, long-term safety beyond approximately 1–2 years, especially for neurocognitive, endocrine, blood pressure and infection risks, is not fully characterised, although current data are encouraging. Finally, external validity for non-white populations and those with diabetes, chronic kidney disease and polymorbidity still needs confirmation, as most participants are high-risk, Western, statin-treated cohorts.

Meta-analysis and Pooled Analysis

A pooled analysis of the BROADWAY and BROOKLYN trials, conducted by Ray et al., examined the effect of obicetrapib on HbA_1c levels at days 84 and 365, as well as its impact on the risk of developing diabetes. Among 1,848 patients evaluated, those receiving combination therapy showed lower post-baseline HbA_1c levels (p<0.02). The HR for new-onset diabetes was 0.77 (p=0.09).30 Obicetrapib lowered HbA_1c levels and showed a trend towards reducing the likelihood of developing new-onset diabetes among individuals with prediabetes and normoglycaemia at baseline, an effect that aligns with the outcomes observed with other CETP inhibitors. A meta-analysis of four large randomised controlled trials (RCTs) of older CETP inhibitors showed a pooled RR of 0.84 for developing new-onset diabetes.31

A meta-analysis by Masson et al. included five RCTs with data from 288 patients. Those treated with obicetrapib experienced a significant decrease in LDL-C by 41.4% (95% CI [-45.7 to -37.1]; p=0.37), ApoB by 26.5% (95% CI [-31.3 to -21.6]; p=0.14) and non-HDL-C by 34.5% (95% CI [-37.0 to -31.6]; p<0.01), compared with placebo. HDL-C levels increased markedly by 157% (95% CI [142.2–172.6]; p=0.01). However, the decrease in triglyceride levels with obicetrapib was not statistically significant.32

Nicholls et al. conducted a pooled analysis of the BROADWAY, BROOKLYN and TANDEM trials to assess the effect of obicetrapib on lipid levels. The drug resulted in a placebo-adjusted reduction in LDL-C of 37.4%, equivalent to a 35 mg/dl decrease. Among patients who had baseline Lp(a) levels between >50 nmol/l and <150 nmol/l, the reduction was 44.8%, or 37.4 nmol/l, similar in absolute terms to those with Lp(a) levels exceeding 150 nmol/l at baseline.33

A meta-analysis of nine RCTs by Bhatti et al. included 3,706 patients. Patients in the obicetrapib arm showed a significant decrease in LDL-C levels by 36.5% (95% CI [41.1–31.9]; p<0.00001), ApoB by 23.8% (95% CI [31.3–17.25]; p<0.00001) and non-HDL-C by 31% (95% CI [-33.9 to -24.1]; p<0.00001) compared with the placebo arm. In the obicetrapib arm, HDL-C also increased significantly by 142.6% (95% CI [116.9–158.4]; p<0.00001). Triglyceride levels did not change significantly. When used in conjunction with ezetimibe, obicetrapib yielded a more substantial decrease in LDL-C by 17.8 %, ApoB by 9.7% and non-HDL-C by 17.5 % in comparison to monotherapy.34

Araújo et al. conducted a meta-analysis of seven RCTs with 3,381 participants. They found that obicetrapib significantly improved the atherogenic lipid parameters: LDL-C levels were reduced by an average of 37.21%, lipoprotein(a) levels by 37.16%, ApoB by 24.65%, non HDL-C levels by 31.90% and triglycerides by 7.2%.35 Obicetrapib increased HDL-C levels by 142% and ApoA-I levels by 52.7%. In line with previous studies, the incidence of new-onset diabetes was reduced by 12% (HR 0.88; p=0.01). There was no difference in terms of any adverse effects or cardiovascular events.

Nicholls et al. assessed the effect of obicetrapib on lipids and clinical outcomes in a pooled analysis of BROOKLYN and BROADWAY studies.36 A daily dose of 10 mg obicetrapib reduced LDL-C by 34 mg/dl (versus 4.0 mg/dl), ApoB by 19 mg/dl (versus 3.0 mg/dl), non-HDL-C by 36 mg/dl (versus 4.0 mg/dl ) and Lp(a) by 9.8 nmol/l, and increased HDL-C by 68 mg/dl (versus 1.0 mg/dl) compared with placebo. The rate of major cardiovascular events was lower with obicetrapib (3.9% versus 5.0%; HR 0.77), with significant risk reduction during 6–12 monthsof treatment (HR 0.60; p=0.04). Coronary events, including death, MI or revascularisation, were reduced (3.2% versus 4.7%; HR 0.68; p=0.048), with the most significant benefit after 6 months (HR 0.45; p=0.003). The levels of LDL-C, ApoB, non-HDL-C, Lp(a) and HDL-C were strongly associated with event rates, supporting obicetrapib’s potential to improve lipid profiles and reduce cardiovascular risk.36

Future Perspectives in Cardiovascular Risk Management

PREVAIL (NCT05202509) is a double-blind, randomised Phase III trial at 591 sites assessing the impact of obicetrapib in patients with ASCVD who remain inadequately controlled despite the maximum tolerated dose of lipid-lowering treatment. Eligible patients have a baseline fasting LDL-C levels ≥1.4 mmol/l (≥55 mg/dl) and fasting triglycerides <4.52 mmol/l (<400 mg/dl). Patients will be randomly assigned 1:1 to receive either 10 mg of obicetrapib or a placebo. The expected median duration of the study for each participant is 32 months.

VINCENT (NCT06496243) is an open-label, 16-week Phase II trial that aims to evaluate effect of treatment on Lp(a) levels in patients with elevated Lp(a) levels at baseline. Participants will initially receive obicetrapib alone for 8 weeks, followed by a combination of obicetrapib and PCSK-9 inhibitor Evolocumab for the subsequent 8 weeks. The study will enrol 30 patients with baseline Lp(a) levels exceeding 125 nmol/l (>50 mg/dl), LDL-C levels >1.8 mmol/l (>70 mg/dl) and triglyceride levels <4.52 mmol/l (<400 mg/dl).

REMBRANDT (NCT06305559) is a randomised, double-blind, placebo-controlled Phase III trial that will involve patients with ASCVD who are not sufficiently controlled on their maximum tolerated therapy. It aims to assess how obicetrapib and ezetimibe affect coronary plaque and inflammatory features, measured by CT angiography at 18 months, compared with a placebo. The study seeks to enrol 300 patients aged ≥45 years who have fasting LDL-C levels exceeding >1.8 mmol/l (>70 mg/ dl) and a minimum of 75 mm³ of non-calcified plaque in the major epicardial coronary arteries.

Figure 2 shows the timeline of various landmark trials of obicetrapib to date.

Figure 2: Timeline of Landmark Trials of Obicetrapib.

The ROSE2 trial compared three groups: obicetrapib alone, obicetrapib and ezetimibe combination and placebo.26 The TANDEM and REMBRANDT (NCT06305559) trials studied combination therapy with obicetrapib and ezetimibe.27 The remaining trials studied obicetrapib monotherapy. CCTA = coronary CT angiography; CV = cardiovascular. Created in BioRender. Pradhan, A. (2026) https://BioRender.com/w4s1b75

Future Place in Therapy: Challenges and Opportunities for Obicetrapib

Several key challenges regarding obicetrapib remain. First, long-term outcomes are yet to be evaluated and hard cardiovascular endpoint trials remain pending. Second, comparative cost-effectiveness needs to be demonstrated relative to PCSK9 inhibitors. Third, integration into treatment algorithms should be elucidated, with positioning alongside PCSK9 inhibitors and inclisiran requiring outcome-based evidence. Finally, the HDL-C paradigm uncertainty persists and the clinical relevance of large HDL-C increases remains debated.

Nevertheless, there are also key opportunities. First is addressing the residual risk in high-risk ASCVD populations via powerful LDL-C and ApoB lowering. Second is that a critical gap in Lp(a) reduction is filled, complementing upcoming small interfering RNA/antisense oligonucleotide therapeutics. Third is expanding access, whereby the oral route of administration, favourable safety and potentially lower cost may make CETP inhibition applicable on a large scale. Finally, it is the place in precision cardiometabolic medicine, which may benefit patients with combined dyslipidaemia, metabolic syndrome or diabetes.

Obicetrapib uniquely targets three essential factors contributing to cardiovascular risk: the overall atherogenic particle load (ApoB and non-HDL-C), the hereditary predisposition to elevated Lp(a) and the necessity for an accessible oral treatment option for patients who are intolerant to statins or prefer not to receive injections. No other existing single medication class offers this comprehensive combination of advantages.

Table 4 compares the different lipid-lowering therapies in terms of the effect on lipid parameters.37–49

Table 4: Effect of Different Lipid-lowering Therapies on Lipid Parameters.

Drug/Class	LDL-C Reduction	HDL-C Increase	Triglyceride Reduction
High-intensity statin37–39	50%	1–10%	10–20%
Moderate-intensity statin	30–49%
Low-intensity statin	<30%
Ezetimibe40,41	15–20%	1–2%	5–10%
PCSK9 inhibitors42,43	60%	5–10%	20–30%
Inclisiran44	50%	5%	12%
Bempedoic acid45	15–20%	5% (reduction)	Neutral
Bile acid sequestrants46	10–25%	Neutral	May increase modestly
Fibrates47	5–20%	5–15%	30–50%
Icosapent ethyl (high-dose EPA)48,49	5–15%	5–10%	20–30%
Obicetrapib29	37–57%	136%	11–17%

EPA = eicosapentaenoic acid; LDL-C = LDL cholesterol; HDL-C = HDL cholesterol; PCSK9 = proprotein convertase subtilisin/kexin type 9.

Conclusion

CETP inhibition has evolved from initial disappointment to renewed optimism. With obicetrapib, a new era of CETP inhibition may be realised. By combining high potency, a favourable safety profile, significant reductions in LDL-C, ApoB and Lp(a) and meaningful improvements in HDL-C, obicetrapib represents a uniquely versatile lipid-lowering therapy.

Pending confirmation in hard cardiovascular outcome trials, obicetrapib stands positioned to become a transformative therapy for ASCVD risk reduction, addressing long-standing unmet needs in lipid management.